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Abstract 
Background: Previously, we validated the mouse thigh infection model to test the therapeutic equivalence of 
generic antibiotic products. Here, our aim was to compare the in vivo efficacy of amikacin products in clinical use in 
Colombia using this animal model.
Results: All except one generic product had the same in vitro potency, judging by the lack of differences on MIC 
and MBC compared with the innovator. However, eight of nine generic products failed in the neutropenic mouse 
thigh infection model to achieve the innovator’s maximum effect (Emax ≤ 5.65 for the generics vs. 6.58 log10 CFU/g for 
the innovator) against Escherichia coli SIG-1, after subcutaneous treatment every 6 h with doses ranging from 1.5 to 
3072 mg/kg per day.
Conclusion: As we demonstrated previously with other antibiotics such as vancomycin, gentamicin and oxacillin, 
the generic products of amikacin failed the in vivo efficacy testing. The therapeutic equivalence should be assessed 
in vivo before clinical approval of generic products.
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Background
Generic substitution of medications is a common prac-
tice [1–3]. Worldwide, there is an abbreviated approval 
pathway for generic drugs of small molecules in which the 
comparative clinical trials are waived [4, 5], after demon-
strating good manufacturing practices and bioequivalence 
in healthy volunteers [6, 7]. Furthermore, bioequivalence 
is waived for intravenous generics under the assump-
tion that pharmaceutical equivalence predicts therapeu-
tic equivalence accurately [8]. This approach has certainly 
rendered the desired economic results [9], but at the price 
of neglecting solid evidence documenting the clinical fail-
ure of intravenous generics of vancomycin and cefuroxime 
[10]. Besides, an animal infection model was validated by 
our group to determine the therapeutic equivalence of 
antimicrobials [11, 12], in which many generic products of 
vancomycin [13], oxacillin [14, 15], gentamicin [16], mero-
penem [17], lincomycin [18], ampicillin [19], and penicillin 
G [20] failed to kill the same number of microorganisms 
as the innovators. Of great concern, those generics of van-
comycin that failed therapeutic equivalence selected the 
resistant subpopulation of Staphylococcus aureus [21], 
whilst therapeutically equivalent generics of ciprofloxa-
cin were indistinguishable from the innovator in terms of 
selection of resistant Pseudomonas aeruginosa [22].
Amikacin is derived from kanamycin and its structure 
confers stability towards many enzymes, mainly from Gram 
negative bacteria, that hydrolyze other aminoglycosides 
[23]. This quality makes it the preferred aminoglycoside to 
prescribe along with a β-lactam to treat diverse nosocomial 
infections. During the execution of this study, the sudden 
discontinuation of the innovator product (Amikin®, Bristol 
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Myers-Squibb) forced us to stop the in  vivo comparative 
experiments. In view of the impossibility of obtaining addi-
tional data, we decided to publish the available evidence.
Results
Antibiotics
Table  1 lists the products tested with their pharmaceutical 
form, lot numbers, manufacturers and distributors. The dem-
onstration of pharmaceutical equivalence for Carlon, Gencol, 
Pisa, Scalpi and Sigma generic products was published previ-
ously by our group [8]. Seven of nine generic products (78 %) 
were produced in Colombia while the other two (Genven and 
Pisa) were made in Venezuela and Mexico, respectively. The 
Farmionni-Lubelca consortium manufactured three (Scalpi, 
Serpharma, Zokumey) of the nine generics tested (33 %), but 
they were analyzed as independent products.
Susceptibility testing
Table 2 shows the MIC and MBC of all products against E. 
coli SIG-1 or P. aeruginosa ATCC 27853. All but one generic 
amikacin product exhibited the same in  vitro efficacy of 
the innovator; the exception was Serpharma, which MIC 
and MBC were 10- and 16-fold higher against both strains 
(P < 0.05 by Dunn’s multiple comparison test). These results 
were reproducible in assays performed in different days.
Reliability of the animal model to test therapeutic 
equivalence
The repeatability of the PD parameters was assessed in 
two different days with the same batch of the innovator 
(batch 99A106). Figure 1 shows that there was no differ-
ence in the non-linear regression (NLR) from two inde-
pendent experiments (P = 0.39 by CFA) with innovator 
amikacin.
Therapeutic equivalence testing
Untreated animals had 7.04–7.34 log10 CFU/g 
when treatment started (0  h) and 9.07–9.78 log10 
CFU/g 24  h later when therapy was finished (net 
growth = 2.24 ± 0.29 log10 CFU/g). All products tested 
yielded valid non-linear regressions describing the 
dose–response relationships obtained by Hill’s Equa-
tion (Fig. 2). The PD parameters for the innovator were 
Emax = 6.58 ± 0.40 log10 CFU/g, ED50 = 272 ± 44.6 mg/
kg per day, and N = 1.02 ± 0.12, while the magnitudes of 
primary (Emax, ED50, N) and secondary (BD, 1LKD, and 
2LKD) parameters of the other nine products are sum-
marized in Table 3.
Except for Carlon product (Fig. 2, panel a), the remain-
ing eight generics failed to reach the innovator’s Emax, 
which ranged from 5.10 to 5.65 log10 CFU/g; in the best 
case, it was one order of magnitude lower than the inno-
vator. It means that the innovator killed ~3.80 million 
microorganisms per gram of tissue at the maximal total 
dose used, whilst the most effective generic killed only 
0.45 million. Although two generics (Gencol and Pisa) 
had greater potency than the innovator comparing their 
bacteriostatic dose (≤110  ±  8.30 vs. 144  ±  12.7  mg/
kg per day), both also had significantly lower Emax 
(P = 0.0003).
Table 1 General description of the amikacin products studied
a The pharmaceutical equivalence (same potency and concentration of the active ingredient) tested by microbiological assay was published elsewhere [8]
Amikacin  
product




BMS (innovator) 1 g in 4 ml Not applicable 99A106 Grove, Ecuador The manufacturer
0.5 g in 2 ml 00G030
05H091A
Bristol-Myers Squibb, Ecuador
Carlon 0.5 g in 2 ml Yes 111V0203 Carlon, Colombia The manufacturer
FormasG 0.5 g in 2 ml No 02525 Vitropharma, Colombia Formas genericas  
farmaceuticas, Colombia
Gencol 0.25 g in 2 ml Yes 0100
0200
Chalver, Colombia The manufacturer
Genven 0.5 g in 2 ml No 904037 Leti for Genven, Venezuela The manufacturer
Pisa 0.5 g in 2 ml Yes 060865
011306
PiSa, Mexico ECAR, Colombia
Quimicol 0.5 g in 2 ml No 3780199 Quimicol, Colombia The manufacturer
Scalpi 0.5 g in 2 ml Yes AK030072 Farmionni-Lubelca, Colombia Farmionni scalpi, Colombia
Serpharma 0.25 g in 2 ml No AK020086 Farmionni-Lubelca, Colombia Serpharma, Colombia
0.1 g in 2 ml AK010172
Sigma (reference) 1 g powder Yes 120K1643 Sigma Chemical Co, USA The manufacturer
Zokumey 0.25 g in 2 ml No AK020035 Farmionni-Lubelca, Colombia Zokumey pharma, 
Colombia
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Discussion
Here, our results with amikacin indicate that almost 
all generics (eight of nine products) failed therapeutic 
equivalence in a head-to-head in  vivo comparison with 
the innovator, independently of their pharmaceutical 
equivalence. These data are similar to previous results 
with other antibiotics [13, 15, 17], reinforcing the idea 
that therapeutic equivalence of generic antimicrobials 
cannot be predicted from pharmaceutical equivalence or 
in vitro testing and therefore requires in vivo studies [11, 
12].
The reliability of the thigh infection model to test the 
efficacy of antibiotics was assessed in two independent 
experiments with the innovator, exhibiting the same PD 
profile (Fig. 1). Besides, the similar in vivo lower efficacy 
of three generic products from the same manufacturer 
(all produced by Farmionni-Lubelca) confirmed the con-
sistency of the model’s findings.
Generic drugs are necessary to regulate drug price. 
But the scant information provided in the abbreviated 
way used by generic manufacturers have arisen some 
theoretical concerns [10, 24, 25] that are experimentally 
supported by our results. In this context, the “contamina-
tion” of bioequivalent generic heparin with oversulfated 
chondroitin sulfate killed approximately 1000 patients 
around the world [26], but generic antibiotics may entail 
an even worse problem: antimicrobial resistance [27, 28]. 
We already demonstrated that so called “bioequivalent” 
generics of vancomycin devoid of therapeutic equiva-
lence do enrich resistant subpopulations of S. aureus after 
exposure for only 12 days in the neutropenic murine thigh 
infection model [21]. In contrast, fully equivalent generic 
products of ciprofloxacin do not exhibit difference on 
resistance profile [22]. Here, similar to the vancomycin 
case, the therapeutically nonequivalent generics of ami-
kacin do not sterilize the thighs even at the highest dose 
(3072 mg/kg per day), leaving at least 3 million bacterial 
cells per gram of tissue exposed to the antibiotic, but alive. 
Then, the risk of resistance is not a minor point [29].
The study by Miller et  al. supports our hypoth-
esis about the impact on resistance of the massive use 
of generic products of amikacin failing therapeutic 
Table 2 Comparison of the in vitro biological potency of the amikacin products studied
Concentrations are expressed as geometric mean and range (Min. and Max) in mg/L
MIC minimal inhibitory concentration, MBC minimal bactericidal concentration
** p value <0.05 by Dunn’s multiple comparison test
Product Escherichia coli SIG-1 Pseudomonas aeruginosa ATCC 27853
MIC Min Max MBC Min Max MIC Min Max MBC Min Max
BMS 1.59 1.00 2.00 1.78 1.00 2.00 4.00 4.00 4.00 10.08 8.00 16.00
Carlon 4.00 4.00 4.00 8.00 8.00 8.00 5.66 4.00 8.00 5.66 4.00 8.00
FormasG 4.00 4.00 4.00 4.00 4.00 4.00 5.66 4.00 8.00 8.00 8.00 8.00
Gencol 2.00 2.00 2.00 2.00 2.00 2.00 4.00 4.00 4.00 8.00 4.00 16.00
Genven 2.00 2.00 2.00 2.00 2.00 2.00 2.83 2.00 4.00 5.66 4.00 8.00
Pisa 2.00 2.00 2.00 2.83 2.00 4.00 4.00 4.00 4.00 11.31 8.00 16.00
Quimicol 2.83 1.00 8.00 4.00 2.00 8.00 3.36 2.00 4.00 6.73 4.00 16.00
Scalpi 2.83 2.00 4.00 2.83 2.00 4.00 4.00 4.00 4.00 4.00 4.00 4.00
Serpharma** 19.03 16.00 32.00 22.63 16.00 32.00 38.05 32.00 64.00 64.00 64.00 64.00
Sigma 1.41 1.00 2.00 2.83 2.00 4.00 4.00 4.00 4.00 8.00 8.00 8.00
Zokumey 2.00 2.00 2.00 4.00 2.00 8.00 4.00 4.00 4.00 11.31 8.00 16.00
Fig. 1 Reliability of the neutropenic murine thigh infection model 
with the innovator of amikacin (BMS) in two independent experi-
ments. The non-significant P value (0.393) from global curve fitting 
analysis (CFA) indicates that the underlying populations are better 
described by a single curve, confirming the model’s reliability for test-
ing therapeutic equivalence
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equivalence [30]. They demonstrated that the amino-
glycoside resistance mechanisms changed with the time 
(comparing studies before and after 1990’s decade) and 
geographical region, according to the increased usage 
of these drugs. According to Miller et  al., the baseline 
resistance level of Citrobacter spp., Enterobacter spp. or 
Klebsiella spp. to amikacin was lower than 20  % before 
1987 (when generic consumption was limited), moment 
at which a continuous rise was observed reaching 60  % 
in countries like Chile, Uruguay, Mexico and Venezuela. 
They also found that it was precisely during this period 
of massive use of generic antimicrobials (after 1987), that 
new enzymes capable to degrade amikacin appeared, 
such as AAC(6′)-I alone or combined with other enzyme 
like AAC(6′)-I  +  AAC(3)-II. Although only speculative 
with the available data, the possibility that therapeutic 
nonequivalent generics could enhance enzymatic resist-
ance deserves scientific testing [29, 31].
There are at least two hypotheses to explain the find-
ings. First, Bau et al. described the X-ray crystal structure 
of amikacin [32], establishing that the spatial relationship 
depends on two bifurcated hydrogen (H) bonds that are 
Fig. 2 In panel a, the in vivo activity of the Carlon generic product of amikacin compared with the innovator (BMS). The non-significant P value 
of the curve-fitting analysis (0.055) indicates that the generic is therapeutically equivalent to the innovator, however the higher data dispersion 
reduced the power of the test to detect significant differences from 87 % to 63 %. In panel b, the in vivo activity of eight generic products of amika-
cin compared with the innovator (BMS). The global curve-fitting analysis (P < 0.05) demonstrates that the generics are described by independent 
curves, characterized by reduced Emax compared with the innovator (see Table 3), indicating that they lack therapeutic equivalence, despite similar 
in vitro activity
Table 3 In vivo pharmacodynamic parameters of nine generics and the innovator product of amikacin
AdjR2 adjusted coefficient of determination, Sy|x standard error of the estimate, CFA curve fitting analysis, Emax maximum effect, SE standard error, ED50 effective dose to 
kill 50 % of Emax, N slope, BD bacteriostatic dose, 1LKD and 2LKD 1- and 2-log kill dose, respectively
Amikacin AdjR2 Sy|x Emax SE ED50 SE N SE BD SE 1LKD SE 2LKD SE P value
(CFA)
BMS (innovator) 0.97 0.37 6.58 0.40 272 44.6 1.02 0.12 144 12.7 266 19.9 490 40.8 NA 
Carlon 0.93 0.65 5.58 0.33 160 27.0 2.01 0.49 132 17.3 190 28.6 288 55.8 0.055
FormasG 0.98 0.36 5.65 0.19 216 19.6 2.01 0.27 169 16.7 242 17.7 357 23.9 0.013
Gencol 0.99 0.24 5.10 0.14 122 11.0 2.26 0.43 110 8.30 157 15.5 248 37.1 0.001
Genven 1.00 0.17 5.36 0.07 209 13.2 3.35 0.31 185 11.9 232 13.6 301 17.8 <0.0001
Pisa 0.98 0.38 5.45 0.22 96 14.1 1.36 0.22 77 9.70 133 16.5 257 40.2 0.001
Quimicol 0.98 0.41 5.53 0.22 241 30.4 2.61 0.56 208 27.9 275 30.1 380 43.2 0.004
Scalpi 0.98 0.38 5.65 0.36 324 48.8 1.35 0.24 228 26.4 384 36.6 684 78.3 0.004
Serpharma 0.99 0.22 5.58 0.17 343 23.6 1.76 0.20 261 17.4 395 21.0 624 39.0 <0.0001
Zokumey 0.95 0.51 5.25 0.24 145 25.7 1.57 0.35 117 18.7 191 30.1 347 68.5 0.044
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necessary for the internal conformation of the amikacin 
molecule. The first H-bond is common with the molecule 
of kanamycin to control the A/B ring orientation but the 
second H-bond is required to define the conformational 
angles around the B/C ring junction. Any subtle change 
in the position of the second H-bond or its lack could 
reduce significantly the in  vivo efficacy of amikacin. To 
test this hypothesis, one could compare simultaneously 
the chemical structure of innovator and generic by X-ray 
crystallography or NMR studies, however, the innovator 
is no longer available. Second, that impurities or different 
excipients might explain the failure of amikacin gener-
ics [33], but it is less likely because the process for semi-
synthesis of amikacin from acylation of kanamycin A is a 
well-known process [34].
Conclusions
In vitro susceptibility tests do not predict the in  vivo 
efficacy of generic products of amikacin. Considering 
the potential impact on antimicrobial resistance of non-
therapeutically equivalent generics, more studies com-
paring the molecular and chemical identity, as well as 
head-to-head studies in validated animal models of infec-
tion should be required before approval of generic ami-
kacin products, although therapeutic equivalence will be 




All amikacin products were bought from reputable drug-
stores and handled following the instructions of each 
manufacturer. The innovator drug was included in all 
experiments as the gold standard [35]. Additionally, the 
reference powder (Sigma Aldrich, USA), a product not 
designed for clinical use, was used.
Bacteria and media
E. coli SIG-1 (an ampicillin-resistant clinical isolate) 
was selected for in  vitro and in  vivo experiments. For 
susceptibility testing, Pseudomonas aeruginosa ATCC 
27853 was used as control [36]. Culture media included 
trypticase soy broth and agar for in vivo studies and cat-
ion-adjusted Mueller–Hinton broth and agar for suscep-
tibility testing (Becton–Dickinson, USA).
Susceptibility testing
Minimal inhibitory (MIC) and bactericidal (MBC) con-
centrations of nine generic products, the reference pow-
der and the innovator of amikacin were determined 
twice by broth microdilution following the Clinical 
Laboratory Standard Institute method [36]. To compare 
the in vitro potency, the differences between geometric 
means were assessed by Kruskal–Wallis (KW) test fol-
lowed by Dunn’s multiple comparison test (GraphPad 
Prism 6.05) [37].
Animal model
The University of Antioquia Animal Experimentation 
Ethics Committee approved the protocol. Six-week-
old, 23–27  g, female murine-pathogen free mice of the 
strain Udea:ICR(CD-1) were used [38]. Mice were ren-
dered neutropenic by injecting two intraperitoneal 
doses of cyclophosphamide (Cytoxan®, Bristol-Myers 
Squibb, Puerto Rico) given 4 days (150 mg/kg) and 1 day 
(100  mg/kg) before infection [39]. An intramuscular 
injection (0.1 mL) per thigh of a log-phase culture with 
~7 log10 CFU of E. coli SIG-1 per mL was used. Two 
hours later (0  h), infected animals began a 24  h-treat-
ment with each amikacin product (N ≥  10 mice/prod-
uct), allocating two animals per dose and using at least 
five total doses that ranged from no effect (1.5 mg/kg per 
day) to maximal effect (3072 mg/kg per day). Each dose 
was administered by the subcutaneous route (0.2  mL) 
every 6  h to optimize fCmax/MIC and fAUC/MIC, the 
pharmacodynamic (PD) indices related to the efficacy of 
amikacin in mice and humans with normal renal func-
tion [40, 41]. Untreated infected control mice were sacri-
ficed just after inoculation (−2 h), at the onset (0 h), and 
at the end of experiment (24 h), while treated mice were 
euthanized at 24 h.
To determine antibacterial efficacy, both thighs of 
each mouse were dissected under aseptic technique and 
homogenized independently in sterile saline (1:10). After 
serial dilutions and manual plating, the cultures were 
incubated for 18 h at 37 °C under air atmosphere before 
colony counting and data registration in a database 
(Microsoft Excel®, USA). In this model, one thigh weighs 
1 g and the limit of detection is 100 CFU/thigh.
Statistical analysis
For each total dose (independent variable), the net anti-
bacterial effect (E, dependent variable) was calculated 
by subtracting the CFU/g obtained in thighs of infected 
mice from the 24 h untreated controls. Nonlinear regres-
sion of the dose–effect data from each product fitted 
to Hill’s model provided the primary PD parameters 
maximum effect (Emax), effective dose killing 50  % of 
the Emax (ED50), and slope (N), as well as the secondary 
PD parameters bacteriostatic dose (BD) and the doses 
required to kill the first (1LKD) and second (2LKD) log 
of bacteria (SigmaPlot 12.3). To test the therapeutic 
equivalence, the magnitudes of these parameters were 
compared (each generic vs. the innovator) by curve fit-
ting analysis (GraphPad Prism 6.05) as was described 
thoroughly elsewhere [13]. The quality of the nonlinear 
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regressions was assessed by the adjusted coefficient of 
determination (adj.R2), the standard error of estimate 
(Sy|x), the fulfillment of the assumptions of normality and 
homoscedasticity (constant variance), and the absence of 
multicollinearity (variance inflation factor). Accepting 
a 5 % chance for a type I error (α-error) and expecting 
residuals’ standard deviations ≤0.5 log, the treatment of 
10 animals per product to compare nine generic prod-
ucts with the innovator confers 87 % power to reject the 
null hypothesis (H0: generics = innovator product) if the 
magnitude of the difference on antibacterial efficacy is 
>1 log10 CFU/g.
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